Tacrolimus Concentrations Measured in Excreted Bile in Liver Transplant Recipients The STABILE Study

Abstract : Tacrolimus (TAC) is the main immunosuppressive drug in liver transplantation. Despite intensive therapeutic drug monitoring (TDM) that relies on whole blood trough concentration (TAC), patients still present with acute cellular rejection or TAC-related toxic effects with concentrations within the therapeutic range. TAC concentration in peripheral blood mononuclear cells (TAC) is considered as an efficient surrogate marker of TAC efficacy. However, it is still not applicable in daily practice. New TDM methods are therefore needed, especially during the early postoperative period. TAC is metabolized in the liver and eliminated through biliary excretion. We therefore hypothesised that TAC concentration measured in excreted bile (TAC) could be a relevant surrogate marker of its efficacy.
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01975939
Contributor : Laurent Jonchère <>
Submitted on : Wednesday, January 9, 2019 - 4:13:27 PM
Last modification on : Thursday, August 8, 2019 - 3:12:02 PM

Identifiers

Citation

Michel Rayar, Camille Tron, Clara Locher, Alexandre Chebaro, Jean-Marie Beaurepaire, et al.. Tacrolimus Concentrations Measured in Excreted Bile in Liver Transplant Recipients The STABILE Study. Clinical Therapeutics, Elsevier, 2018, 40 (12), pp.2088-2098. ⟨10.1016/j.clinthera.2018.10.015⟩. ⟨hal-01975939⟩

Share

Metrics

Record views

31